126 related articles for article (PubMed ID: 2560520)
1. New analogues of mifepristone with more dissociated antiprogesterone activities.
Philibert D; Hardy M; Gaillard-Moguilewsky M; Nique F; Tournemine C; Nédélec L
J Steroid Biochem; 1989; 34(1-6):413-7. PubMed ID: 2560520
[TBL] [Abstract][Full Text] [Related]
2. History and perspectives of antiprogestins from the chemist's point of view.
Teutsch G; Philibert D
Hum Reprod; 1994 Jun; 9 Suppl 1():12-31. PubMed ID: 7962457
[TBL] [Abstract][Full Text] [Related]
3. Antiprogesterone and antiglucocorticoid actions of RU 486 on rabbit mammary gland explant cultures. Evidence for a persistent inhibitory action of residual progesterone upon the mammary tissue.
Jahn GA; Houdebine LM; Djiane J
J Steroid Biochem; 1987 Oct; 28(4):371-7. PubMed ID: 3669658
[TBL] [Abstract][Full Text] [Related]
4. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.
Attardi BJ; Burgenson J; Hild SA; Reel JR
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):277-88. PubMed ID: 15120421
[TBL] [Abstract][Full Text] [Related]
5. RU 486 (mifepristone). A short overview of its mechanisms of action and clinical uses at the end of 1996.
Baulieu EE
Ann N Y Acad Sci; 1997 Sep; 828():47-58. PubMed ID: 9329823
[TBL] [Abstract][Full Text] [Related]
6. Syntheses and antigestagenic activity of mifepristone derivatives.
Hödl C; Raunegger K; Strommer R; Ecker GF; Kunert O; Sturm S; Seger C; Haslinger E; Steiner R; Strauss WS; Schramm HW
J Med Chem; 2009 Mar; 52(5):1268-74. PubMed ID: 19216549
[TBL] [Abstract][Full Text] [Related]
7. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
Papp C; Schatz F; Krikun G; Hausknecht V; Lockwood CJ
Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
[TBL] [Abstract][Full Text] [Related]
8. [Clinical use of RU 486: control of the menstrual cycle and effect on the hypophyseal-adrenal axis].
Gaillard RC; Herrmann W
Ann Endocrinol (Paris); 1983; 44(5):345-6. PubMed ID: 6675522
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological testing of 4'-(dimethylamino)-17 beta-hydroxy-17 alpha-(1-propynyl)benzo[12,12a]-11 alpha,18-cyclo-12a,12b-dihomo-13 alpha-estr-4-en-3-one: an interesting RU 38 486 analog.
Ottow E; Beier S; Elger W; Fritzemeier KH; Neef G; Wiechert R
Steroids; 1994 Mar; 59(3):185-9. PubMed ID: 8048150
[TBL] [Abstract][Full Text] [Related]
10. Nongenomic uterine relaxing effect of RU 486 (mifepristone) prior to its antiprogesterone activity in the human pregnancy.
Perusquía M; Espinoza J; Navarrete E
Steroids; 2009 Oct; 74(10-11):825-31. PubMed ID: 19464306
[TBL] [Abstract][Full Text] [Related]
11. Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor.
Baulieu EE
Science; 1989 Sep; 245(4924):1351-7. PubMed ID: 2781282
[TBL] [Abstract][Full Text] [Related]
12. Tonic support of luteinizing hormone secretion by adrenal progesterone in the ovariectomized monkey replaced with midfollicular phase levels of estradiol.
Xiao E; Xia-Zhang L; Shanen D; Ferin M
J Clin Endocrinol Metab; 1997 Jul; 82(7):2233-8. PubMed ID: 9215299
[TBL] [Abstract][Full Text] [Related]
13. Antigestogens.
Baird DT
Br Med Bull; 1993 Jan; 49(1):73-87. PubMed ID: 8324617
[TBL] [Abstract][Full Text] [Related]
14. Effect of RU-486 and related compounds on the proliferation of cultured macrophages.
Roberts CP; Parthasarathy S; Gulati R; Horowitz I; Murphy AA
Am J Reprod Immunol; 1995 Oct; 34(4):248-56. PubMed ID: 8579763
[TBL] [Abstract][Full Text] [Related]
15. Antiprogestins: mechanism of action and contraceptive potential.
Spitz IM; Croxatto HB; Robbins A
Annu Rev Pharmacol Toxicol; 1996; 36():47-81. PubMed ID: 8725382
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
Fuhrmann U; Hess-Stumpp H; Cleve A; Neef G; Schwede W; Hoffmann J; Fritzemeier KH; Chwalisz K
J Med Chem; 2000 Dec; 43(26):5010-6. PubMed ID: 11150172
[TBL] [Abstract][Full Text] [Related]
17. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell stromelysin-1 and prolactin expression.
Schatz F; Papp C; Aigner S; Krikun G; Hausknecht V; Lockwood CJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):188-93. PubMed ID: 8989257
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 11' imidazolyl antiprogestins and mesoprogestins.
Nickisch K; Elger W; Santhamma B; Garfield R; Killeen Z; Amelkina O; Schneider B; Meister R
Steroids; 2014 Dec; 92():45-55. PubMed ID: 25174783
[TBL] [Abstract][Full Text] [Related]
19. The antiprogesterone steroid RU-486 does not impair gonadotropin-stimulated luteal adenylyl cyclase activity or gonadotropin release by pituitary cells.
Rojas FJ; O'Conner JL; Asch RH
J Steroid Biochem; 1985 Dec; 23(6A):1053-8. PubMed ID: 3937946
[TBL] [Abstract][Full Text] [Related]
20. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
